

## Special Issue

# Breast Cancer and Hormone-Related Therapy

### Message from the Guest Editor

Breast cancer remains the most common malignancy in women and over 70% of all breast tumors are initially characterized as being “hormonally sensitive” based on expression of estrogen receptor alpha (ER $\alpha$ ). More recently, a newer class of drugs known as CDK4/6 inhibitors have demonstrated profound activity in the metastatic setting and are now commonly used in combination with aromatase inhibitors as a first line therapy for patients with recurrent ER $\alpha$  positive tumors. In addition to ER $\alpha$ , a number of other hormone activated transcription factors have been shown to be expressed in breast cancer, and substantial efforts have been made to determine the contribution of these factors in breast cancer development, progression, and treatment. This Special Issue relates to emerging hormonal therapies, both for newly diagnosed and resistant forms of breast cancer, the molecular mechanisms by which such therapies elicit their anti-cancer effects and the cellular processes that are ultimately responsible for treatment failure.

---

### Guest Editor

Dr. John R. Hawse  
Mayo Clinic, Rochester, MN, USA

---

### Deadline for manuscript submissions

10 August 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/136547](https://mdpi.com/si/136547)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)